GlassScriptPhysician profile
Taylor Benoit Mulkey
NPI 1760679203
$6,657.10
in general payments reported to CMS, 2019-2025
34 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 82% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $94.21 · 2021: $361 · 2022: $1,468 · 2023: $1,152 · 2024: $1,628 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,982 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,981.67 |
| Education | $213.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $1,061.64 | 2019-2025 | |
| Abbvie INC. | $860.98 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $559.61 | 2019-2025 | Ilumya, Winlevi, Blu-U |
| Arcutis Biotherapeutics, INC. | $552.25 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $437.61 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $340.43 | 2019-2024 | |
| Pfizer INC. | $300.61 | 2019-2025 | |
| Merz North America, INC. | $285.05 | 2019-2022 | |
| Allergan, INC. | $224.80 | 2020-2022 | |
| Lilly USA, LLC | $196.99 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $175.62 | 2019-2025 | Bimzelx |
| Dermavant Sciences, INC. | $159.62 | 2023 | Vtama |
| Incyte Corporation | $157.62 | 2021-2025 | Opzelura |
| Organogenesis INC. | $155.70 | 2021-2024 | Puraply Wound Matrix |
| E.R. Squibb & Sons, L.L.C. | $141.67 | 2024 | Sotyktu |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $123.46 | 2022 | |
| Almirall LLC | $123.28 | 2021-2025 | Klisyri, Seysara |
| Regeneron Healthcare Solutions, INC. | $115.39 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $105.72 | 2023-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $92.84 | 2019-2024 | |
| Galderma Laboratories, L.P. | $82.09 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Kerecis Limited | $59.21 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Epi Health, LLC | $55.69 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.86 | 2022-2023 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.92 | 2021-2024 | Jublia, Cabtreo |
| Convatec INC. | $35.68 | 2025 | |
| Leo Pharma INC. | $34.79 | 2019-2023 | Adbry |
| Smith+Nephew, INC. | $25.37 | 2023 | Grafix Pl |
| Biofrontera INC. | $21.95 | 2025 | |
| Genentech USA, INC. | $17.65 | 2019 | |
| Dermira, INC. | $15.84 | 2019 | |
| Bioventus LLC | $15.27 | 2022 | |
| Verrica Pharmaceuticals INC. | $14.72 | 2025 | Ycanth |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Mulkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.